Bone health, intellectual disability and epilepsy: An observational community‐based study
Acta Neurologica Scandinavica · 2022-06 · 145 (6) · 753-761
DOI: 10.1111/ane.13612 ↗At a glance
Beobachtungsstudie in Acta Neurologica Scandinavica, published online on 2022-03-17. Written by Robert Winterhalder and 7 co-authors. Institution: Oxleas NHS Foundation Trust, Sidcup, UK. Major MEDLINE topics: Epilepsy, Intellectual Disability, Vitamin D Deficiency. Cited 21 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
OBJECTIVES: Intellectual disability (ID) and epilepsy are independent risk factors for osteoporosis. Diverse predisposing factors influence this, for example in ID, genetics and poor nutrition and in epilepsy, anti-seizure medication (ASM). Around 25% people with ID have epilepsy, majority treatment resistant. ASMs polypharmacy is common. However, little is known about the bone-related characteristics of this vulnerable group. A prospective observational cohort study of bone profile across a community ID Epilepsy service was undertaken to understand this. MATERIALS & METHODS: Participants were on minimum 2 years of ASMs. Baseline demographics, epilepsy data, bone metabolism biomarkers, bone mineral density (BMD) and vitamin D levels were collected. Doses needed to correct vitamin D insufficiency/deficiency were calculated. RESULTS: At baseline, of 104 participants, 92 (90.2%) were vitamin D insufficient/deficient. Seventy-six (73.1%) had a DEXA scan, 50 of whom-in the osteopaenic/osteoporotic range. DEXA scores between ambulant and non-ambulant patients were significantly different (p = .05) but not for ID severity. A high alkaline phosphatase (ALP) predicted lower vitamin D levels. Borderline significance (p = .06) in calcium levels between normal and high ALP was identified. There were no significant associations between parathyroid hormone, inorganic phosphate and magnesium levels, with vitamin D status or DEXA hip T-scores. Normalizing vitamin D levels (mean 101.4 nmol/L) required an average of 1951IU cholecalciferol daily. CONCLUSIONS: Vitamin D deficiency is highly prevalent in people with ID and epilepsy treated with ASMs impacting likely on their bone health. Screening with vitamin D levels, ALP and DEXA in this group should be pro-actively and routinely considered.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Oxleas NHS Foundation Trust, Sidcup, UK.
- University of Exeter Medical School, Truro, UK.
- Cornwall Partnership NHS Foundation Trust, Truro, UK.
- Cornwall Intellectual Disability Epilepsy Research (CIDER), University of Plymouth Peninsula School of Medicine, Truro, UK.
- Hertfordshire Partnership University NHS Foundation Trust, Essex, UK.
- School of Pharmacy and Pharmaceutical Sciences Trinity College, Dublin 2, Ireland.
ORCID profiles: Rohit Shankar
Cite
APA
Winterhalder, R., McCabe, J., Young, C., Lamb, K., Sawhney, I., Jory, C., O'Dwyer, M., & Shankar, R. (2022). Bone health, intellectual disability and epilepsy: An observational community‐based study. Acta Neurologica Scandinavica, 145(6), 753-761. https://doi.org/10.1111/ane.13612
Vancouver
Winterhalder R, McCabe J, Young C, Lamb K, Sawhney I, Jory C, et al. Bone health, intellectual disability and epilepsy: An observational community‐based study. Acta Neurologica Scandinavica. 2022;145(6):753-761. doi:10.1111/ane.13612
BibTeX
@article{Winterhalder2022,
author = {Winterhalder, Robert and McCabe, Joanne and Young, Charlotte and Lamb, Kirsten and Sawhney, Indermeet and Jory, Caryn and O'Dwyer, Maire and Shankar, Rohit},
title = {Bone health, intellectual disability and epilepsy: An observational community‐based study},
journal = {Acta Neurologica Scandinavica},
year = {2022},
volume = {145},
number = {6},
pages = {753--761},
doi = {10.1111/ane.13612}
}
EUVIMED